Genentech, Inc.

Genentech, Inc. is an American biotechnology company headquartered in South San Francisco, California, and is widely recognized as a pioneer in the biotechnology industry. The company's core mission is dedicated to pursuing groundbreaking science to discover, develop, manufacture, and commercialize medicines for people facing serious and life-threatening diseases.

Genentech's extensive product portfolio spans various therapeutic areas, including oncology, ophthalmology, neuroscience, immunology, and rare blood disorders. Key products include targeted antibody therapies for cancer, such as Herceptin and Rituxan, as well as treatments for ophthalmic conditions like Vabysmo and Susvimo. The company has been instrumental in developing the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

As a wholly-owned subsidiary of the Swiss pharmaceutical giant Roche since 2009, Genentech operates as the headquarters for Roche's pharmaceutical operations in the United States, while its Research and Early Development (gRED) unit maintains an independent, entrepreneurial spirit. In recent news, Genentech is showcasing its ophthalmology portfolio at ARVO 2026, with data on Vabysmo and Susvimo, and has seen positive Phase II results for its obesity/overweight candidate, Petrelintide. The company continues to integrate AI and data science into drug discovery and was recognized by TIME as one of the most influential health companies in 2026.